Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Takara Bio Inc. ( (JP:4974) ).
Takara Bio Inc. reported a decline in financial performance for the six months ending September 30, 2025, with net sales dropping by 4.9% and a significant loss in profit compared to the previous year. The company has revised its financial forecast downward, indicating challenges in maintaining profitability, which could impact its market position and stakeholder confidence.
The most recent analyst rating on (JP:4974) stock is a Hold with a Yen931.00 price target. To see the full list of analyst forecasts on Takara Bio Inc. stock, see the JP:4974 Stock Forecast page.
More about Takara Bio Inc.
Takara Bio Inc. operates in the biotechnology industry, focusing on the development and commercialization of products related to genetic engineering and cell therapy. The company is listed on the Tokyo Stock Exchange and is known for its innovative solutions in life sciences.
Average Trading Volume: 403,638
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen109.9B
See more insights into 4974 stock on TipRanks’ Stock Analysis page.